|
Preclinical characterization of pretargeted radioimmunotherapy (PRIT) with GD2-SADA, a self-assembling and disassembling bispecific fusion protein. |
| |
|
Employment - Y-mAbs Therapeutics |
Stock and Other Ownership Interests - Y-mAbs Therapeutics |
Patents, Royalties, Other Intellectual Property - Y-mAbs Therapeutics |
| |
|
Employment - Y-mAbs Therapeutics |
| |
|
Employment - Y-mAbs Therapeutics |
| |
|
Employment - Y-mAbs Therapeutics |
Stock and Other Ownership Interests - Lundbeck; Novo Nordisk; Y-mAbs Therapeutics |
Patents, Royalties, Other Intellectual Property - Y-mAbs Therapeutics |
| |
|
Employment - Y-mAbs Therapeutics |
| |
|
Employment - Y-mAbs Therapeutics A/S |
| |
|
Employment - Y-mAbs Therapeutics |
| |
|
Consulting or Advisory Role - Sanofi |
| |
|
Employment - Y-mAbs Therapeutics |
Stock and Other Ownership Interests - Novo Nordisk; Y-mAbs Therapeutics |
| |
|
Employment - Y-mAbs Therapeutics |
| |
|
No Relationships to Disclose |